Top Story

NOBORI 1: Low TLR, no stent thrombosis with biodegradable polymer DES at 5 years

January 30, 2015

Five-year data demonstrate that the Nobori drug-eluting stent with biodegradable polymer was safe and durable in patients with de novo coronary artery lesions.

The randomized, prospective, controlled, multicenter NOBORI 1 trial included 363 patients with up to two de novo lesions in two epicardial vessels who were randomly assigned to the Nobori DES with biodegradable polymer (Terumo; n=238) or the Taxus Express/Liberté DES (Boston Scientific; n=125). Previously reported results from the trial demonstrated that the Nobori DES was associated with a significant reduction of in-segment and in-stent late loss at 9 months after implantation, according to background information in the study.

Meeting News Coverage

Blood transfusions during CABG increased risk for pneumonia

January 30, 2015
Patients had a greater risk for developing postoperative pneumonia if they received red blood cell transfusions during or after isolated CABG surgery, according to data…
In the Journals

Degree of hypertension control did not affect pregnancy complications

January 30, 2015
In pregnant women, risk for pregnancy loss, high-level neonatal care and overall maternal complications did not differ based on tight control or less-tight control of…
Robert Harrington

Experts provide in-depth analysis of key findings presented at AHA 2014

January 29, 2015
The American Heart Association Scientific Sessions in November featured the presentation of several major studies with practice-changing implications for the field of…
David Frankel, MD, FHRS

Increased use of CRT could help reduce hospitalizations for HF

January 29, 2015
For patients with HF, poor dietary and alcohol choices can lead to increased risk for hospitalization. In fact, recent research has demonstrated that hospitalization for…
More News Headlines »
CME
Debating the Differences and Nuances of Antiplatelet Therapy in ACS and PCI: Not a One-Size-Fits-All?

Debating the Differences and Nuances of Antiplatelet Therapy in ACS and PCI: Not a One-Size-Fits-All?

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC.

More »
Meeting News Coverage Video
thumbnail for video 3945938325001

Kirk N. Garratt, MD: Prolonged DAPT beneficial in patients with paclitaxel-eluting stents

December 16, 2014
CHICAGO — In this video, Kirk N. Garratt, MD, of the Lennox Hill Hospital, New York, outlines results of a study…
More »
CME
Severe Hypertriglyceridemia: Confronting the Complex Issues in Etiology and Treatment

Severe Hypertriglyceridemia: Confronting the Complex Issues in Etiology and Treatment

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent, yet modifiable, risk factor for atherosclerotic disease, pancreatitis, and…
More »
morganatic-roan